Nantahala Capital Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $21.6M | Buy |
|
|||||
|
2025
Q1 | $15.4M | Buy |
|
|||||
|
2024
Q4 | $14.5M | Buy |
|
|||||
|
2024
Q3 | $22.2M | Buy |
|
|||||
|
2024
Q2 | $17.3M | Buy |
|
|||||
|
2024
Q1 | $19.5M | Sell |
|
|||||
|
2023
Q4 | $12.3M | Sell |
|
|||||
|
2023
Q3 | $10.5M | Sell |
|
|||||
|
2023
Q2 | $20M | Sell |
|
|||||
|
2023
Q1 | $31.7M | Sell |
|
|||||
|
2022
Q4 | $38M | Sell |
|
|||||
|
2022
Q3 | $31.8M | Sell |
|
|||||
|
2022
Q2 | $25.2M | Buy |
|
|||||
|
2022
Q1 | $44.4M | Buy |
|
|||||
|
2021
Q4 | $46.6M | Buy |
|
|||||
|
2021
Q3 | $30.1M | Buy |
|
|||||
|
2021
Q2 | $25.4M | Buy |
|
|||||
|
2021
Q1 | $28.3M | Sell |
|
|||||
|
2020
Q4 | $37.7M | Buy |
|
|||||
|
2020
Q3 | $10.7M | Buy |
|
|||||
|
2020
Q2 | $10.3M | Buy |
|